Study findings support the recent FDA approval of the immunotherapy agent for patients whose cancers have high number of mutations.

The new approach blocks the interaction between cancer cells and immune receptors, showing promise in mice.

Breast cancer stem cells from patients with different racial and ethnic backgrounds showed important differences in activation of immune response-related genes in mouse models.

A new study finds that significant symptoms in young and Black patients are more likely to be under-recognized.

A U-M Rogel Cancer study provides an updated, more comprehensive look at trends for this rare, aggressive form of breast cancer over the last four decades.

The new approach could help doctors to separate aggressive stage 0 breast cancer from non-aggressive forms, sparing some women unnecessary mastectomies.